← Leaderboards
X. Long Zheng
University Of Kansas Medical Center
$11,062,949
Attributed
$11,958,957
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $966.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,958,957 · 7
By mechanism
R01$10,162,505 · 6
P01$1,796,452 · 1
Top collaborators
- Xiaohui Zhang4 shared
Others in their field
Top investigators on “Metalloproteases”
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Athan Kuliopulos · Tufts Medical Center$19,336,433
- Stephen C. Blacklow · Massachusetts Institute Of Technology$15,488,971
- Konstantin Ichtchenko · New York University School Of Medicine$12,971,230
- J. Edwin Blalock · University Of Alabama At Birmingham$10,917,281
- Carl Peter Blobel · Hospital For Special Surgery$10,844,661
Research focus
MetalloproteasesVon Willebrand FactorPlasmaThrombotic Thrombocytopenic PurpuraHemostatic FunctionThrombosisSiteMolecularBlood PlateletsRegulationRecombinantsMass Spectrum AnalysisSyndromeEndothelial CellsCleaved CellSurface Plasmon ResonancePlayNovel TherapeuticsEnzymesHydrogenLaboratoriesDeuteriumMediatingStructure
Grant awards (29)
Pathogenesis of thrombotic microangiopathies$519,069
R01 · FY2025 · HL · contact PI
Mechanism underlying cofactor-dependent proteolysis of von Willebrand Factor$447,049
R01 · FY2025 · HL · contact PI
Pathogenesis of thrombotic microangiopathies$508,688
R01 · FY2024 · HL · contact PI
Mechanism underlying cofactor-dependent proteolysis of von Willebrand Factor$438,108
R01 · FY2024 · HL · contact PI
Pathogenesis of thrombotic microangiopathies$519,069
R01 · FY2023 · HL · contact PI
Mechanism underlying cofactor-dependent proteolysis of von Willebrand Factor$447,049
R01 · FY2023 · HL · contact PI
Mechanism underlying cofactor-dependent proteolysis of von Willebrand Factor$459,810
R01 · FY2022 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$457,707
R01 · FY2022 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$457,707
R01 · FY2021 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$457,707
R01 · FY2020 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$444,245
R01 · FY2019 · HL · contact PI
Pathogenesis of Thrombotic Microangiopathy$455,395
R01 · FY2018 · HL · contact PI
Pathogenesis of Thrombotic Microangiopathy$455,395
R01 · FY2017 · HL · contact PI
Pathogenesis of Thrombotic Microangiopathy$455,395
R01 · FY2016 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$377,202
R01 · FY2016 · HL · contact PI
Pathogenesis of Thrombotic Microangiopathy$467,145
R01 · FY2015 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$371,543
R01 · FY2015 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$414,462
R01 · FY2014 · HL · contact PI
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura$409,174
R01 · FY2013 · HL · contact PI
Cofactor-Dependent Regulation of ADAMTS13 Function$345,360
P01 · FY2013 · HL · contact PI
Cofactor-Dependent Regulation of ADAMTS13 Function$362,773
P01 · FY2012 · HL · contact PI
Cofactor-Dependent Regulation of ADAMTS13 Function$362,773
P01 · FY2011 · HL · contact PI
Cofactor-Dependent Regulation of ADAMTS13 Function$362,773
P01 · FY2010 · HL · contact PI
Cofactor-Dependent Regulation of ADAMTS13 Function$362,773
P01 · FY2009 · HL · contact PI
Structure and Function of ADAMTS13 Metalloprotease$314,796
R01 · FY2009 · HL · contact PI
Structure and Function of ADAMTS13 Metalloprotease$314,796
R01 · FY2008 · HL · contact PI
Structure and Function of ADAMTS13 Metalloprotease$314,796
R01 · FY2007 · HL · contact PI
Structure and Function of ADAMTS13 Metalloprotease$324,198
R01 · FY2006 · HL · contact PI
Structure and Function of ADAMTS13 Metalloprotease$332,000
R01 · FY2005 · HL